title: Cancer: a "stem-cell" disease?
abstract: BACKGROUND
  Nowadays, we believe that cancer is a genetic disease. We focus on the genetic targets and epigenetic changes in a tumor. Remarkably, many crucial signal pathways in a malignant cell involve "stem-ness" genes. The prevalence of stem-ness in cancer suggests that cancer has a stem-cell origin and is a stem-cell disease.
  
  
  OBJECTIVE
  The observation that many innate stem-ness properties are easily interchangeable with malignant hallmarks needs to be further elucidated. There appears to be a malignant potential in every stem cell and a stem cell potential in every malignant cell. I hypothesize that cancer is a stem-cell disease rather than a genetic disease.
  
  
  METHODS
  We will use homeobox genes to endow a certain progenitor cell with specific stem-ness properties and confer different stem-cell phenotypes to the particular cell type in a hierarchical manner. We will demonstrate that an earlier homeobox gene plus a genetic defect (such as Pten loss) tend to form a more virulent tumor, while a later homeobox gene plus the same genetic defect tend to express a more indolent phenotype. Importantly, we will show that in clinically relevant cancer subtypes, those with worse clinical outcomes may paradoxically harbor fewer genetic mutations than those with better outcomes do.
  
  
  CONCLUSIONS
  The recognition that cancer is a stem-cell disease will instigate major paradigm shifts in our basic understanding of cancer. Many fundamental principles of oncology, such as multistep carcinogenesis, need to be reconciled. The realization that cancer is a stem-cell disease will also have profound clinical implications on personalized care. Many aspects of our current clinical trials need to be reevaluated.
authors: Department of Genitourinary Medical Oncology, Unit 1374, The University of Texas MD Anderson Cancer Center, 1155 Pressler Street, Houston, TX 77030-3721, USA. stu@mdanderson.org.
authors: Shi-Ming
authors: SM
authors: Tu
references: Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):E3395-404
references: 23184966
references: Cell. 2011 Jun 24;145(7):1023-35
references: 21703447
references: Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10516-21
references: 22689991
references: Cancer. 1959 May-Jun;12(3):573-83
references: 13652104
references: Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1:11896-903
references: 12909713
references: Nat Commun. 2012;3:1122
references: 23047680
references: Nature. 1984 Jun 7-13;309(5968):552-6
references: 6203040
references: Proc Natl Acad Sci U S A. 1986 Oct;83(19):7307-10
references: 3463969
references: Lab Invest. 1994 Jan;70(1):6-22
references: 8302019
references: Proc Natl Acad Sci U S A. 1964 Sep;52:654-61
references: 14212538
references: Cancer Treat Res. 2010;154:v-239
references: 20645140
references: Nature. 2012 Aug 23;488(7412):522-6
references: 22854781
references: Science. 2004 Nov 26;306(5701):1568-71
references: 15567866
references: Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10895-900
references: 9380731
references: Basic Life Sci. 1978;12:3-25
references: 378217
references: Genetics. 2000 Sep;156(1):297-304
references: 10978293
references: Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1397-402
references: 21220315
references: Nature. 2010 Jul 29;466(7306):632-6
references: 20639864
references: Lancet Oncol. 2002 Aug;3(8):508-13
references: 12147437
references: Nature. 2006 Jun 29;441(7097):1068-74
references: 16810241
references: Proc Natl Acad Sci U S A. 2011 May 10;108(19):7950-5
references: 21498687
references: Science. 2012 Aug 10;337(6095):730-5
references: 22855427
references: Nature. 2011 Feb 10;470(7333):214-20
references: 21307934
references: Arthritis Res. 2000;2(1):59-64
references: 11219390
references: Nature. 2011 May 13;474(7350):212-5
references: 21572395
references: Nature. 2012 Aug 23;488(7412):527-30
references: 22854777